EP1593380A2 - Utilisation d'un oligosaccharide pour prévenir la coagulation du sang dans un circuit extracorporel - Google Patents
Utilisation d'un oligosaccharide pour prévenir la coagulation du sang dans un circuit extracorporel Download PDFInfo
- Publication number
- EP1593380A2 EP1593380A2 EP05015221A EP05015221A EP1593380A2 EP 1593380 A2 EP1593380 A2 EP 1593380A2 EP 05015221 A EP05015221 A EP 05015221A EP 05015221 A EP05015221 A EP 05015221A EP 1593380 A2 EP1593380 A2 EP 1593380A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- sulpho
- glucopyranosyl
- methyl
- oligosaccharide
- uronic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Definitions
- the invention relates to the use of a certain oligosaccharide for the manufacture of a medicament for preventing blood clotting in extracorporeal blood circuits. Further the invention relates to a pharmeuceutical composition for said use.
- thrombin The prime function of thrombin is the cleavage of fibrinogen to generate fibrin monomers, which form an insoluble gel by cross-linking, thereby initiating thrombus formation.
- UFH and LMWH have thrombolytic properties, i.e. they induce dissolution of the thrombus formed.
- oligosaccharides especially oligosaccharides described in EP 84,999 and US 5,378,829, highly selectively inhibit factor Xa via antithrombin III (ATIII) but do not have any activity on thrombin.
- ATIII antithrombin III
- those oligosaccharides inhibit thrombus formation, e.g. as occurring in extracorporeal blood circuits.
- a synthetic oligosaccharide which is a selective inhibitor of factor Xa, acting via antithrombin III, is useful for preventing blood clotting in patients with an extracorporeal blood circuit.
- the use of the oligosaccharide according to this invention results in effective and safe inhibition of blood clotting, e.g. in patients undergoing haemodialysis, without increased bleeding risks.
- a preferred oligosaccharide for the use according to this invention is the pentasaccharide with the formula methyl O-(2-deoxy-2-sulphoamino-6-O-sulpho- ⁇ -D-glucopyranosyl)-(1 ⁇ 4)-O-( ⁇ -D-glucopyranosyl uronic acid)-(1 ⁇ 4)-O-(2-deoxy-2-sulphoamino-3,6-di-O-sulpho- ⁇ -D-glucopyranosyl)-(1 ⁇ 4)-O-(2-O-sulpho- ⁇ -L-idopyranosyl, uronic acid)-(1 ⁇ 4)-2-deoxy-2-sulphoamino-6-O-sulpho- ⁇ -D-glucopyranoside or a pharmaceutically acceptable salt thereof (i.e.
- salts with counter-ions like hydrogen or, more preferably, alkali or earth-alkali metal ions, like sodium, calcium, or magnesium), having the structure: Particularly preferred is its decasodium salt, known by its code name Org 31540 or SR 90107A (described in Chemical Synthesis to Glycosaminoglycans, Supplement to Nature 1991, 350 , 30-33).
- extracorporeal blood circuits includes circuits and intravenous infusion lines used for haemodialysis, renal dialysis, haemofiltration, and the like.
- Preferred extracorporeal cicuits are those used in the treatment of haemodialysis patients.
- the oligosaccharide can be administered at several stages of the treatment.
- the oligosaccharide is administered as an intravenous injection to the mammal undergoing treatment.
- the mammal is a human.
- Another route of administration of the oligosaccharide is the introduction thereof into a (dialysis) circuit by other means, e.g. by injecting it either gradually or at once into the system upstream of the dialysis membrane simultaneously with the introduction of the blood into the circuit.
- the lines and/or further equipment of the extracorporeal circuit can be furnished with the oligosaccharide, preferably by way of a coating (but not limited to this).
- the oligosaccharide may be adsorbed in the materials of parts of the equipment, e.g. in the membranes used for dialysis.
- the oligosaccharide may be administered enterally or parenterally (especially via the subcutaneous or intravenous route) or may be administered via an external source ( vide supra ), and for humans preferably in a dosage of 0,001-10 mg per kg body weight per dialysis. More preferably, the pentasaccharide is administered at doses of between 0.30 mg and 30 mg per patient per dialysis.
- the oligosaccharide may be used alone or may be presented as a pharmaceutical composition. Accordingly, the present invention further provides a pharmaceutical composition for preventing blood clotting in an extracorporeal blood circuit comprising said oligosaccharide together with pharmaceutically acceptable auxiliaries and optionally other therapeutic agents.
- compositions include e.g. those suitable for oral, sublingual, subcutaneous, intravenous, intramuscular, transdermal. transmucosal, local, or rectal administration, and the like, all in unit dosage forms for administration.
- the active ingredient may be presented as discrete units, such as tablets capsules, powders, granulates, solutions, suspensions, and the like.
- the pharmaceutical composition of the invention may be presented in unit-dose or multi-dose containers, e.g.
- injection liquids in predetermined amounts for example in sealed vials and ampoules, and may also be stored in a freeze dried (lyophlized) condition requiring only the addition of sterile liquid carrier, e.g. water, prior to use.
- sterile liquid carrier e.g. water
- the oligosaccharide may be compressed into solid dosage units, such as pills, tablets, or be processed into capsules or suppositories.
- the oligosaccharide can be applied as a fluid composition, e.g. as an injection preparation, in the form of a solution, suspension, emulsion, or as a spray, e.g. a nasal spray.
- a fluid composition e.g. as an injection preparation
- a spray e.g. a nasal spray
- pharmaceutically acceptable polymers may be used as a matrix for the oligosaccharide.
- coatings are included, in which the oligosaccharide is chemically (e.g. covalently) linked to the surface without loss of its activity. Any parmaceutically acceptable coating may be suitable for this purpose, prepared according to methods conventional in the art.
- Suitable carriers with which the oligosaccharides of the invention can be administered as solid compositions include lactose, starch, cellulose derivatives and the like, or mixtures thereof, used in suitable amounts.
- aqueous suspensions, isotone saline solutions and sterile injectable solutions may be used, containing pharmaceutically acceptable dispersing agents and/or wetting agents, such as propylene glycol or butylene glycol.
- compositions according to the invention may also be presented in the form of a veterinary composition, such compositions may be prepared by methods conventional in the art.
- the invention further includes a pharmaceutical composition, as hereinbefore described, in combination with packaging material suitable for said composition, said packaging material including instructions for the use of the composition for the use as hereinbefore described.
- the pentasaccharide Org 31540 / SR 90107 A as a representative compound for use according to the present invention, has been subject to a pilot clinical study in 12 patients undergoing chronic intermittent haemodialysis.
- block A 10 mg of Org 31540 / SR 90107 A was administered.
- block B 8, 6, and 4 mg of Org 31540 / SR 90107 A were used.
- Medication was given as an intravenous bolus predialysis for 1 dialysis each week.
- Efficacy was assessed by determining patency of the dialyzer, buffer and bubble chamber, every hour during dialysis by visual examination and by blood sampling of specific coagualtion, heamatologic and biochemical parameters.
- Safety was assessed by evaluating major and minor bleeding complications each dialysis.
- the pentasaccharide Org 31540 / SR 90107 A is a safe (no increased haemorrhagic risks) and effective (at several doses) anticoagulant to prevent clotting in the extracorporeal blood circuit in haemodialysis patients.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- External Artificial Organs (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05015221A EP1593380A3 (fr) | 1997-05-27 | 1998-05-22 | Utilisation d' un oligosaccharide pour prévenir la coagulation du sang dans un circuit extracorporel |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97201586 | 1997-05-27 | ||
EP97201586 | 1997-05-27 | ||
EP98932096A EP0984785B1 (fr) | 1997-05-27 | 1998-05-22 | Utilisation d'un oligosaccharide pour empecher la coagulation du sang dans les circuits sanguins extra-corporels |
EP05015221A EP1593380A3 (fr) | 1997-05-27 | 1998-05-22 | Utilisation d' un oligosaccharide pour prévenir la coagulation du sang dans un circuit extracorporel |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP98932096A Division EP0984785B1 (fr) | 1997-05-27 | 1998-05-22 | Utilisation d'un oligosaccharide pour empecher la coagulation du sang dans les circuits sanguins extra-corporels |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1593380A2 true EP1593380A2 (fr) | 2005-11-09 |
EP1593380A3 EP1593380A3 (fr) | 2008-06-11 |
Family
ID=8228366
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP98932096A Expired - Lifetime EP0984785B1 (fr) | 1997-05-27 | 1998-05-22 | Utilisation d'un oligosaccharide pour empecher la coagulation du sang dans les circuits sanguins extra-corporels |
EP05015221A Withdrawn EP1593380A3 (fr) | 1997-05-27 | 1998-05-22 | Utilisation d' un oligosaccharide pour prévenir la coagulation du sang dans un circuit extracorporel |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP98932096A Expired - Lifetime EP0984785B1 (fr) | 1997-05-27 | 1998-05-22 | Utilisation d'un oligosaccharide pour empecher la coagulation du sang dans les circuits sanguins extra-corporels |
Country Status (12)
Country | Link |
---|---|
US (3) | US6391339B1 (fr) |
EP (2) | EP0984785B1 (fr) |
JP (2) | JP2002503270A (fr) |
AT (1) | ATE307596T1 (fr) |
AU (1) | AU8211398A (fr) |
BR (1) | BR9809478A (fr) |
CA (1) | CA2289522A1 (fr) |
DE (1) | DE69832066T2 (fr) |
DK (1) | DK0984785T3 (fr) |
ES (1) | ES2251090T3 (fr) |
NO (1) | NO325142B1 (fr) |
WO (1) | WO1998053829A1 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2289522A1 (fr) * | 1997-05-27 | 1998-12-03 | Akzo Nobel Nv | Utilisation d'un oligosaccharide pour empecher la coagulation du sang dans les circuits sanguins extra-corporels |
FR2804328B1 (fr) | 2000-01-27 | 2002-03-15 | Hospal Ind | Membrane semi-permeable non thrombogene et procede de fabrication |
JP2006096668A (ja) * | 2002-11-08 | 2006-04-13 | Ono Pharmaceut Co Ltd | エラスターゼ阻害剤と血液凝固系および/または線溶系酵素阻害剤との組み合わせからなる医薬 |
JP5925693B2 (ja) * | 2009-12-01 | 2016-05-25 | エクステラ・メディカル・コーポレーション | 表面固定した多糖類を用いた、血液からのサイトカイン除去法 |
WO2013188073A1 (fr) | 2012-06-13 | 2013-12-19 | Exthera Medical, Llc | Utilisation de l'héparine et des hydrates de carbone pour traiter le cancer |
CA2928866C (fr) | 2013-11-08 | 2021-11-09 | Exthera Medical Corporation | Procedes pour diagnostiquer des maladies infectieuses a l'aide de milieux d'adsorption |
JP2017513636A (ja) | 2014-04-24 | 2017-06-01 | エクスセラ メディカル コーポレイション | 高流量を用いて血液から細菌を除去するための方法 |
US11911551B2 (en) | 2016-03-02 | 2024-02-27 | Exthera Medical Corporation | Method for treating drug intoxication |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0084999A1 (fr) * | 1982-01-15 | 1983-08-03 | D.R.O.P.I.C. (Société Civile) | Procédé de synthèse organique d'oligosaccharides, correspondant à des fragments de muco-polysaccharides naturels, nouveaux oligosaccharides obtenus et leurs applications biologiques |
US5378829A (en) * | 1990-04-23 | 1995-01-03 | Akzo N.V. | Sulfated glycosaminoglycanoid derivatives of the heparin and heparan sulfate type |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2002A (en) * | 1841-03-12 | Tor and planter for plowing | ||
DE3008993A1 (de) * | 1980-03-08 | 1981-10-01 | Röhm Pharma GmbH, 6100 Darmstadt | Pharmazeutische zubereitungen |
US4331697A (en) * | 1980-09-02 | 1982-05-25 | Teijin Limited | Novel heparin derivative, method for production thereof, and method for rendering biomedical materials antithrombotic by use of the novel heparin derivative |
US4818816A (en) * | 1981-04-28 | 1989-04-04 | Choay, S.A. | Process for the organic synthesis of oligosaccharides and derivatives thereof |
US4987223A (en) * | 1981-12-23 | 1991-01-22 | Choay S.A. | Derivatives of the uronic acid |
US4801583A (en) * | 1982-01-15 | 1989-01-31 | Choay S.A. | Oligosaccharides and their biological applications |
JPS63218691A (ja) * | 1987-03-09 | 1988-09-12 | Rikagaku Kenkyusho | 新規な5糖類化合物及びその製造法並びに抗凝血及び抗血栓剤 |
EP0300099A1 (fr) * | 1987-07-20 | 1989-01-25 | Akzo N.V. | Pentasaccharides |
US5256559A (en) * | 1988-03-04 | 1993-10-26 | Biogen, Inc. | Methods and compositions for inhibiting platelet aggregation |
US5252213A (en) * | 1989-06-20 | 1993-10-12 | University Of Washington | Dry dialysate composition |
WO1993005825A1 (fr) * | 1991-09-20 | 1993-04-01 | Baxter International Inc. | Procedes permettant de reduire la thrombogenicite de biomateriaux |
ITPD940054A1 (it) * | 1994-03-23 | 1995-09-23 | Fidia Advanced Biopolymers Srl | Polisaccaridi solfatati |
US6391369B1 (en) * | 1996-03-27 | 2002-05-21 | Bunge Foods Corporation | Selectively hydrogenated high oleic oil compositions and process |
IL120722A (en) * | 1996-05-08 | 1999-07-14 | Akzo Nobel Nv | Polysulfated tetrasaccharide derivatives and pharmaceutical compositions containing them |
CA2289522A1 (fr) * | 1997-05-27 | 1998-12-03 | Akzo Nobel Nv | Utilisation d'un oligosaccharide pour empecher la coagulation du sang dans les circuits sanguins extra-corporels |
-
1998
- 1998-05-22 CA CA002289522A patent/CA2289522A1/fr not_active Abandoned
- 1998-05-22 DE DE69832066T patent/DE69832066T2/de not_active Expired - Lifetime
- 1998-05-22 WO PCT/EP1998/003174 patent/WO1998053829A1/fr active IP Right Grant
- 1998-05-22 DK DK98932096T patent/DK0984785T3/da active
- 1998-05-22 AT AT98932096T patent/ATE307596T1/de active
- 1998-05-22 EP EP98932096A patent/EP0984785B1/fr not_active Expired - Lifetime
- 1998-05-22 JP JP50025099A patent/JP2002503270A/ja active Pending
- 1998-05-22 BR BR9809478-5A patent/BR9809478A/pt not_active Application Discontinuation
- 1998-05-22 US US09/424,626 patent/US6391339B1/en not_active Expired - Lifetime
- 1998-05-22 AU AU82113/98A patent/AU8211398A/en not_active Abandoned
- 1998-05-22 ES ES98932096T patent/ES2251090T3/es not_active Expired - Lifetime
- 1998-05-22 EP EP05015221A patent/EP1593380A3/fr not_active Withdrawn
-
1999
- 1999-11-26 NO NO19995800A patent/NO325142B1/no not_active IP Right Cessation
-
2001
- 2001-11-02 US US10/005,793 patent/US20020040012A1/en not_active Abandoned
-
2006
- 2006-08-14 US US11/464,259 patent/US20070197637A1/en not_active Abandoned
-
2009
- 2009-08-25 JP JP2009193834A patent/JP2010013455A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0084999A1 (fr) * | 1982-01-15 | 1983-08-03 | D.R.O.P.I.C. (Société Civile) | Procédé de synthèse organique d'oligosaccharides, correspondant à des fragments de muco-polysaccharides naturels, nouveaux oligosaccharides obtenus et leurs applications biologiques |
US5378829A (en) * | 1990-04-23 | 1995-01-03 | Akzo N.V. | Sulfated glycosaminoglycanoid derivatives of the heparin and heparan sulfate type |
Non-Patent Citations (7)
Also Published As
Publication number | Publication date |
---|---|
DE69832066D1 (de) | 2005-12-01 |
US20070197637A1 (en) | 2007-08-23 |
NO325142B1 (no) | 2008-02-11 |
NO995800L (no) | 1999-11-26 |
US6391339B1 (en) | 2002-05-21 |
CA2289522A1 (fr) | 1998-12-03 |
JP2010013455A (ja) | 2010-01-21 |
EP0984785A1 (fr) | 2000-03-15 |
ES2251090T3 (es) | 2006-04-16 |
DE69832066T2 (de) | 2006-07-13 |
ATE307596T1 (de) | 2005-11-15 |
WO1998053829A1 (fr) | 1998-12-03 |
AU8211398A (en) | 1998-12-30 |
NO995800D0 (no) | 1999-11-26 |
EP1593380A3 (fr) | 2008-06-11 |
BR9809478A (pt) | 2000-06-20 |
JP2002503270A (ja) | 2002-01-29 |
DK0984785T3 (da) | 2006-01-30 |
EP0984785B1 (fr) | 2005-10-26 |
US20020040012A1 (en) | 2002-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070197637A1 (en) | Use of oligosaccharide for preventing blood clotting in extracorporeal blood circuits | |
Herbert et al. | SR123781A, a synthetic heparin mimetic | |
RU2153506C2 (ru) | Дерматансульфат или его соль, противотромбозные средства, способ предупреждения или лечения тромбозов, способ предупреждения или лечения синдрома рассеянной интраваскулярной коагуляции, способ лечения инфаркта миокарда | |
Ryan et al. | Dose finding study of a low molecular weight heparin, Innohep, in haemodialysis | |
Wolf | Low-molecular-weight heparin | |
Ryan et al. | Antithrombotic properties of dermatan sulphate (MF 701) in haemodialysis for chronic renal failure | |
Nenci | Dermatan sulphate as an antithrombotic drug | |
Briggsb et al. | Long-term use of the low molecular weight heparin tinzaparin in haemodialysis | |
Anastassiades et al. | A low-molecular-weight heparin (Kabi 2165,‘Fragmin’) in repeated use for haemodialysis: Prevention of clotting and prolongation of the venous compression time in comparison with commercial unfractionated heparin | |
Kaiser | Anticoagulant and antithrombotic actions of recombinant hirudin | |
MXPA99010965A (en) | Use of oligosaccharide for preventing blood clotting in extracorporeal blood circuits | |
Ireland et al. | Low molecular weight heparin in haemodialysis for chronic renal failure: dose finding study of CY222 | |
Moriniere et al. | Low-molecular-weight heparin Fraxiparin® in chronic hemodialysis: a dose-finding study | |
Zhang et al. | Improvement of patency in small veins following dextran and/or low-molecular-weight heparin treatment | |
EP1024813A1 (fr) | Utilisation d'oligosaccharides sulfates comme inhibiteurs des maladies cardiovasculaires | |
Cofrancesco et al. | The effect of dermatan sulfate on in vitro human plasma coagulation, platelet aggregation and βTG/PF4 release | |
AU2001291549A1 (en) | Antithrombotic compositions | |
Oguma et al. | Clinical effect of low molecular weight heparin (fragmin) on DIC: a multicenter cooperative study in Japan | |
Sie et al. | Neutralization of dermatan sulfate in vitro and in vivo by protamine sulfate and polybrene | |
Carter | New developments in acute anticoagulation therapy: What improvements over traditional heparin are on the horizon? | |
Bauer et al. | Anticoagulant properties of three mucopolysaccharides used in rheumatology | |
AU726883B2 (en) | Use of sulfated oligosaccharides as inhibitors of cardiovascular disease | |
Olsson et al. | Polyphloretine phosphate as an inhibitor of platelet adhesion. Comparison with acetylsalicylic acid and dipyridamole | |
Bergqvist et al. | Low-dose heparin | |
JPH10251153A (ja) | アスピリンおよび抗−Xaオリゴ糖の組合せを含有する組成物ならびにアスピリンと任意的に組み合わせた抗−Xaオリゴ糖の使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20050713 |
|
AC | Divisional application: reference to earlier application |
Ref document number: 0984785 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 7/02 20060101ALI20080507BHEP Ipc: A61P 43/00 20060101ALI20080507BHEP Ipc: A61K 31/70 20060101AFI20050915BHEP |
|
17Q | First examination report despatched |
Effective date: 20090107 |
|
AKX | Designation fees paid |
Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20090718 |